Article Text

Download PDFPDF
Case series
Thrombectomy 6-24 hours after stroke in trial ineligible patients
  1. Shashvat M Desai1,
  2. Marcelo Rocha1,
  3. Bradley J Molyneaux1,
  4. Matthew Starr1,
  5. Cynthia L Kenmuir1,
  6. Bradley A Gross2,
  7. Brian Thomas Jankowitz2,
  8. Tudor G Jovin1,2,
  9. Ashutosh P Jadhav1,2
  1. 1 Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
  2. 2 Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  1. Correspondence to Dr Ashutosh P Jadhav, Stroke Institute, University of Pittsburgh, Pittsburgh, PA 15218, USA; jadhavap{at}


Background and purpose The DAWN and DEFUSE-3 trials demonstrated the benefit of endovascular thrombectomy (ET) in late-presenting acute ischemic strokes due to anterior circulation large vessel occlusion (ACLVO). Strict criteria were employed for patient selection. We sought to evaluate the characteristics and outcomes of patients treated outside these trials.

Methods A retrospective review of acute ischemic stroke admissions to a single comprehensive stroke center was performed during the DAWN trial enrollment period (November 2014 to February 2017) to identify all patients presenting in the 6–24 hour time window. These patients were further investigated for trial eligibility, baseline characteristics, treatment, and outcomes.

Results Approximately 70% (n=142) of the 204 patients presenting 6–24 hours after last known well with NIH Stroke Scale score ≥6 and harboring an ACLVO are DAWN and/or DEFUSE-3 ineligible, most commonly due to large infarct burden (38%). 26% (n=37) of trial ineligible patients with large vessel occlusion strokes received off-label ET and 30% of them achieved functional independence (modified Rankin Scale 0–2) at 90 days. Rates of symptomatic intracranial hemorrhage and mortality were 8% and 24%, respectively

Conclusion Trial ineligible patients with large vessel occlusion strokes receiving off-label ET achieved outcomes comparable to DAWN and DEFUSE-3 eligible patients. Patients aged <80 years are most likely to benefit from ET in this subgroup. These data indicate a larger population of patients who can potentially benefit from ET in the expanded time window if more permissive criteria are applied.

  • thrombectomy
  • stroke
  • intervention

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Conception and design: SMD, APJ. Acquisition of data: SMD. Analysis and interpretation of data: All: Drafting the article: SMD, APJ. Critically revising the article: All.:Administrative/technical/material support: All: Study supervision: APJ, TGJ.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests TGJ: Consultant, Neuravi (steering committee - modest), Codman Neurovascular (DSMB - modest), Stryker Neurovascular (PI DAWN - unpaid), Fundacio Ictus (PI REVASCAT - unpaid). Stock: Anaconda, Silk Road, Blockade Medical (modest).

  • Patient consent Not required.

  • Ethics approval Institutional review board of University of Pittsburgh.

  • Provenance and peer review Not commissioned; externally peer reviewed.